Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP003601) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
Nanobody anti-HER2 MIRC213
|
|||||
| Synonyms |
Nanobody MIRC213
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Expression System | Escherichia coli BL21 (DE3) | |||||
| Selection Method | Phage display | |||||
| Highest Status | Research | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS048 | [1] | ||||
| Scaffold Name | Nanobody | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Inhibitor | Tools for prolonging nanobody-based radiotracer plasma half-life and enhancing the efficacy of tumor-targeted radionuclide therapy | IC50: 17.09 nM | Peking University | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT05622240 | Click to show the Detail | |||||
| Indication | Breast Cancer | |||||
| Phase | Early Phase I | |||||
| Title | 99mTc-MIRC213 SPECT/?CT for the Detection of HER2-positive Breast Cancer | |||||
| Status | Recruiting | |||||
| Sponsor | Peking Union Medical College Hospital | |||||